Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Curevac Netherlands B V is managing 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct examiners and 2 distinct art units, showing a diversified approach to its intellectual property. The busiest examiner for the company is VAN DRUFF, SYDNEY, who is responsible for 1 of the pending actions. This means the 2 pending office actions are split evenly among the 2 distinct examiners currently assigned to the company's cases.
Practitioners should note that the prosecution strategy involves navigating 2 distinct art units, which may require addressing different examination styles within the Biotechnology & Pharmaceuticals sector. The presence of 2 distinct examiners suggests that the company's technical claims are broad enough to span multiple specialized units at the USPTO. This diversification across 2 distinct art units can be beneficial, as it reduces the risk of the entire portfolio being stalled by a single examiner's interpretation. However, it also requires managing two separate sets of deadlines and examiner interactions, as each of the 2 pending office actions is being reviewed by a different individual in a different art unit.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| §103 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VAN DRUFF, SYDNEY | 1 | 55.3% | +32.0% |
| BAUSCH, SARAE L | 1 | 29.7% | +45.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17261997 | METHOD OF PREPARING SUBJECT-SPECIFIC IMMUNOGENIC COMPOSITIONS BASED ON A NEO OPEN-READING-FRAME PEPTIDE DATABASE | BAUSCH, SARAE L | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17263258 | CANCER VACCINES FOR UTERINE CANCER | VAN DRUFF, SYDNEY | 19d |
| 17261997 | METHOD OF PREPARING SUBJECT-SPECIFIC IMMUNOGENIC COMPOSITIONS BASED ON A NEO OPEN-READING-FRAME PEPTIDE DATABASE | BAUSCH, SARAE L | — |
| Art Unit | Apps |
|---|---|
| 1643 | 1 |
| 1699 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17263258 | CANCER VACCINES FOR UTERINE CANCER | VAN DRUFF, SYDNEY | 1643 | §103 | Final Rejection | 19d | Pending | Jan 26, 2021 |
| 17261997 | METHOD OF PREPARING SUBJECT-SPECIFIC IMMUNOGENIC COMPOSITIONS BASED ON A NEO OPEN-READING-FRAME PEPTIDE DATABASE | BAUSCH, SARAE L | 1699 | §101§112 | Non-Final OA | — | Pending | Jan 21, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCurevac Netherlands B V has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Sydney Van Druff has the most, with 1 of Curevac Netherlands B V's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
